Little Green Pharma (ASX:LGP) has received its largest $5 million R&D rebate to date, reflecting significant expenditure during FY2023. This rebate is in addition to the $360,000 received by subsidiary Rest Mind Sciences. LGP shares are up 12%, trading at 14 cents at 11:25 am AEDT, following these developments.
Read the full story here
Written by: Bianca Gimondo
Published on February 4, 2024 at 04:22PM
Source: The Market Online (opens in new tab)